CA-RUBEDO/BEIERSDORF
Rubedo Life Sciences, a biotechnology company specializing in cellular senescence and anti-aging research, announced today a multi-year strategic partnership with German multinational beauty company Beiersdorf AG to develop innovative skin care products that address the effects of cellular aging. Beiersdorf additionally joins Rubedo as a strategic investor, having participated in its recent Series A financing round through its Oscar & Paul Corporate Venture Capital Fund.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423657886/en/
Rubedo Life Sciences scientists (Photo: Business Wire)
The partnership between Rubedo and Beiersdorf revolves around the exploration of novel compounds derived from Rubedo's extensive research programs, specifically targeting cellular senescence. Senescent cells accumulate with age and may contribute to age-related skin changes and pathologies. These compounds will be sourced from Rubedo's topical dermatology program, which have senolytic and anti-inflammatory properties.
As part of the partnership, Beiersdorf will conduct in vitro and in silico studies, and will conduct rigorous assessments of the identified compounds from Rubedo. The collaborative effort will culminate in in vivo human studies, aimed at validating the efficacy of the selected compounds in cosmetic skin care formulations. Rubedo shall be eligible to receive milestones and royalty payments.
“We are thrilled to announce our partnership with Beiersdorf, a recognized global leader in the cosmetics and skin care industry to develop new products that address skin aging,” said Marco Quarta, CEO of Rubedo Life Sciences. “For over 140 years, Beiersdorf has been a worldwide leader in skin care with global brands like NIVEA, Eucerin, and La Prairie. By combining Rubedo's expertise in cellular senescence with Beiersdorf's complementary expertise in skin care innovation, this partnership may revolutionize the landscape of skin care products, offering consumers new solutions that treat cellular aging for healthy and youthful-looking skin.”
“Our mission is to define the future of skincare through breakthrough innovation,” commented Beiersdorf CEO Vincent Warnery. “By partnering with Rubedo and combining cutting-edge expertise from both sides, we aim to redefine the standards in anti-age skincare.”
Rubedo's innovative approach to compound development, coupled with Beiersdorf's leading global brand platforms, is poised to set new standards in anti-aging skin care and develop new solutions for the multibillion face care market.
About Rubedo Life Sciences
Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, technology, and life sciences, with expertise in drug development and commercialization from both large pharma and leading biotech companies. The company is based in Sunnyvale, CA. For additional information, visit www.rubedolife.com.
About Beiersdorf AG
Beiersdorf has stood for innovative, high-quality skin care products as well as pioneering skin research for more than 140 years. Leading international brands such as NIVEA, the world’s no. 1 skin care brand*, Eucerin (dermocosmetics), La Prairie (selective cosmetics), and Hansaplast/Elastoplast (plasters and wound care) are cherished by millions of people around the world day after day. Renowned brands such as Aquaphor, Coppertone, Chantecaille, Labello, 8x4, atrix, Hidrofugal, Maestro, and Florena round off our extensive portfolio in the Consumer Business Segment. Through the wholly owned affiliate tesa SE, Beiersdorf is also a globally leading manufacturer of technical adhesive tapes and provides self-adhesive solutions to industry, craft businesses, and consumers.
The Hamburg-based company generated sales of €9.5 billion as well as an operating result (EBIT) of €1.3 billion in fiscal year 2023. Beiersdorf has more than 21,000 employees worldwide, who are connected by shared core values, a strong corporate culture, and the Beiersdorf purpose Care Beyond Skin. With its business strategy, the company pursues a multi-year investment program focusing on competitive, sustainable growth. The program is consistent with the ambitious sustainability agenda, with which Beiersdorf is generating clear added value for consumers, society, and the environment.
* Source: Euromonitor International Limited; NIVEA by umbrella brand name in the categories Body Care, Face Care, and Hand Care; in retail value terms, 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423657886/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik13.1.2026 15:01:00 CET | Press release
Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh. The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, “R&D organ
Wasabi Raises $70M in New Equity to Power the Next Era of Data Infrastructure13.1.2026 15:00:00 CET | Press release
At a $1.8 billion valuation, backed by L2 Point and Pure Storage, the company scales AI-first cloud storage to meet the explosive demands of modern data Wasabi Technologies, the Hot Cloud Storage company, today announced a $70 million equity funding round led by L2 Point Management with participation from Pure Storage and existing investors including Fidelity Management & Research Company. The new round values Wasabi at $1.8 billion and brings the company’s total funding to over $600 million. The capital will be used to accelerate Wasabi’s expansion into AI infrastructure, broaden its global footprint, and enhance its product portfolio to meet the growing data demands of enterprises and AI developers worldwide. “We’re ushering in the next generation of cloud storage, powering data-intensive workloads like generative AI and autonomous systems,” said David Friend, co-founder and CEO of Wasabi Technologies. “This funding underscores Wasabi’s strong market position and continued growth as
HumanX Amsterdam Reveals First 100 Speakers, Bringing Global AI Powerhouses to Europe13.1.2026 14:00:00 CET | Press release
Anton Osika (Lovable), May Habib (Writer), Jan Oberhauser (n8n) & Eléonore Crespo (Pigment) headline a diverse lineup spanning AI innovation and enterprise adoption HumanX, the global AI summit for executives and innovators, today unveiled its first 100 speakers and opened registration for HumanX Amsterdam, taking place 22–24 September 2026 at The RAI. Built by the team behind Money20/20, Shoptalk, and HLTH, HumanX Amsterdam brings the proven formula of its #1 U.S. flagship event and ecosystem gathering to Europe. The event convenes over 2,500 senior leaders focused on moving beyond the hype to drive practical, responsible AI implementation across industries. Speakers Leading the Conversation The first 100 speakers include AI company founders such as Anton Osika (Lovable), Jan Oberhauser (n8n), May Habib (Writer), Arvind Jain (Glean), and Jarek Kutylowski (DeepL), alongside executives scaling AI in the enterprise, including Clay Bavor (Sierra), Des Traynor (Intercom), and Eléonore Cres
GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 14:00:00 CET | Press release
The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are
Wolfspeed Achieves 300mm Silicon Carbide (SiC) Technology Breakthrough13.1.2026 14:00:00 CET | Press release
300mm SiC Technology, Enabling Scalable Platforms for AI Infrastructure, AR/VR, and Advanced Power DevicesAnnouncement highlights:Strategic Technology Milestone – Wolfspeed has produced a single crystal 300mm (12-inch) silicon carbide wafer, representing a major advancement in the evolution of silicon carbide technology and a critical enabler for emerging applications. Technology leadership for Next-Gen Applications – Backed by one of the industry’s largest and most foundational silicon carbide IP portfolios, with over 2,300 issued and pending patents worldwide, Wolfspeed is accelerating the commercialization of 300mm technology to power next-generation platforms including AI infrastructure, augmented reality/virtual reality (AR/VR) and advanced power devices. Strengthening U.S. Semiconductor Leadership & Supply Chain Resilience –The company’s vertically integrated supply chain, from crystal growth to advanced packaging, supports national goals around compound semiconductor independenc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom